<DOC>
	<DOCNO>NCT01677572</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability multiple dos Aducanumab ( recombinant , fully human anti-Aβ IgG1 mAb ) participant prodromal mild Alzheimer 's Disease ( AD ) . The secondary objective study assess effect cerebral amyloid plaque content measure florbetapir-fluorine-18 ( 18F-AV-45F-AV-45 ) positron emission tomography ( PET ) imaging , assess multiple dose serum concentration Aducanumab evaluate immunogenicity Aducanumab multiple dose administration population .</brief_summary>
	<brief_title>Multiple Dose Study Aducanumab ( BIIB037 ) ( Recombinant , Fully Human Anti-Aβ IgG1 mAb ) Participants With Prodromal Mild Alzheimer 's Disease</brief_title>
	<detailed_description>The study consist placebo-controlled period study week 54 , follow long-term extension study week 388 . The placebo-controlled period conduct stagger , parallel group design , first 3 treatment arm conduct parallel , 2 treatment arm subsequently begin parallel , 2 additional treatment arm begin parallel , last 2 treatment arm subsequently begin parallel . Qualifying participant enter long-term extension period 42 additional dos active drug first 3 year LTE . Furthermore , last participant Arms 8 9 EOS Visit third year LTE , eligible participant able continue treatment beyond third year LTE .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Participants must ambulatory . Participants must meet follow core clinical criterion determine Investigator : Prodromal Alzheimer 's Disease ( AD ) ( criterion must apply ) : Mini Mental State Examination ( MMSE ) score 2430 ( inclusive ) spontaneous memory complaint objective memory loss define free recall score ≤27 Free Cued Selective Reminding Test ( FCSRT ) global Clinical Dementia Rating Scale ( CDR ) score 0.5 absence significant level impairment cognitive domain essentially preserved activity daily live , absence dementia . OR Mild Alzheimer 's Disease ( AD ) criterion ( criterion must apply ) : Mini Mental State Examination ( MMSE ) score 2026 ( inclusive ) global Clinical Dementia Rating Scale ( CDR ) 0.5 1.0 meeting National Institute AgingAlzheimer 's Association core clinical criterion probable AD . Participants must positive florbetapir positron emission tomography ( PET ) amyloid scan . Participants must consent apolipoprotein E ( ApoE ) genotyping . Apart clinical diagnosis Alzheimer 's Disease ( AD ) , participant must good health . Must reliable informant caregiver . Key Any medical neurological condition ( Alzheimer 's Disease ) might contribute cause participant 's cognitive impairment . Have stroke Transient Ischemic Attack ( TIA ) unexplained loss consciousness past 1 year . Clinically significant psychiatric illness past 6 month . Seizure past 3 year . Poorly control diabetes mellitus . History unstable angina , myocardial infarction , chronic heart failure , clinical significant conduction abnormality within 1 year prior Screening . Indication impair renal liver function . Have human immunodeficiency virus ( HIV ) infection . Have significant systematic illness infection past 30 day . Brain MRI show evidence acute subacute micro macrohemorrhage , great 4 microhemorrhages , cortical infarct great one 1 lunar infarct . Any contraindication brain MRI positron emission tomography ( PET ) scan . Negative positron emission tomography ( PET ) scan amyloidtargeting ligand within 48 week Screening . Clinically significant 12lead electrocardiogram ( ECG ) abnormality . Alcohol substance abuse past 1 year . Taking blood thinner ( except aspirin prophylactic dose less ) Have change medication dos medication past 4 week . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>